Director Bruno Lucidi Receives Equity Awards and Exercises RSUs at Atea Pharmaceuticals

This Form 4 filing reports equity transactions by Bruno Lucidi, a director of Atea Pharmaceuticals, Inc. On June 18, 2026, Lucidi received 29,600 shares of common stock through the exercise of vested restricted stock units (RSUs) that had fully vested on that date. Additionally, he was granted 26,700 new RSUs that will vest on the earlier of the next annual stockholders meeting after June 18, 2026 or June 18, 2027, subject to continued service. He also received 37,700 stock options with an exercise price of $4.36 per share, which vest monthly over 12 months starting June 18, 2026, with full vesting by June 18, 2027. Following these transactions, Lucidi holds 142,350 shares of common stock directly, plus the newly granted RSUs and options. The filing was signed by an attorney-in-fact on June 23, 2026.